CLINICAL TRIALS
The SAGA Clinical Trials Center has numerous open clinical studies and is currently enrolling patients with cancer in adults over 18 years of age.
Search clinical trials
Buscar estudios clínicos
LUNG
| Name | Description | View study | Patologhy |
|---|---|---|---|
| TROPION-Lung08 | Dato-DXd Plus Study of Pembrolizumab versus Pembrolizumab alone in the first-line treatment of subjects with advanced or metastatic NSCLC without actionable genomic alterations (TROPION-Lung08) | Ver Estudio | Lung cancer |
| MK1084-001 | Phase 1, multicenter, open-label study to evaluate the safety, tolerability, pharmacokinetics, and efficacy of MK-1084 as monotherapy and in combination with pembrolizumab in subjects with advanced KRAS G12C mutant solid tumors | Ver Estudio | Lung, Colon, Pancreas Cancer |
| MK2870-004 | Phase 3, randomized, open-label study of MK 2870 versus chemotherapy (docetaxel or pemetrexed) in previously treated advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) with EGFR mutations or other genomic alterations. | Ver Estudio | Lung cancer |
| TAS6417-301 | Safety and efficacy study of TAS6417 (zipalertinib) in combination with standard chemotherapy for non-small cell lung cancer with EGFR exon 20 insertion mutations. | Ver Estudio | Lung cancer |
| MK3475-01H | KEYMAKER-U01 Phase I/II Umbrella study of novel conjugated treatments in patients with previously treated stage IV non-small cell lung cancer. | Ver Estudio | Lung cancer |
| MK3475-01G | KEYMAKER-U01 Phase 2 umbrella study with rotating cohorts of investigational agents in combination with pembrolizumab, with or without platinum-based chemotherapy, in treatment-naïve participants with stage IV non-small cell lung cancer (NSCLC) | Ver Estudio | Lung cancer |
| MK3475-01I | KEYMAKER-U01 – 01 I Phase 2 umbrella study in previously treated participants with stage IV squamous non-small cell lung cancer (NSCLC) | Ver Estudio | Lung cancer |
Multitumoral
| Name | Description | View study | Patologhy |
|---|---|---|---|
| MK1XXX-001 | The purpose of this study is to investigate the pharmacokinetic efficacy and safety of MK-1XXX in patients with solid tumors with KRASG12C mutation, in first or second line of treatment. Amendment 4 (Lung, Colon (2L), Ovary, Pancreas) | Ver Estudio | Túmores sólidos |
Solid Tumor
| Name | Description | View study | Patologhy |
|---|---|---|---|
| MK0472-001 | Phase I-Ib open-label study of MK-0472 monotherapy and in combination with Pembrolizumab in patients with advanced/metastatic solid tumors | Ver Estudio | Solid tumors |
Gastric or gastroesophageal junction cancer
| Name | Description | View study | Patologhy |
|---|---|---|---|
| Destiny-Gastric05 | Multicenter, randomized, open-label, phase 3 trial of trastuzumab deruxtecan (Enhertu®) plus chemotherapy plus or minus pembrolizumab versus chemotherapy plus trastuzumab plus or minus pembrolizumab as first-line treatment in participants with HER2-positive unresectable or locally advanced or metastatic gastric or gastroesophageal junction cancer (Destiny-Gastric05). | Ver Estudio | Gastric or gastroesophageal junction cancer. |
Prostate cancer
| Name | Description | View study | Pathology |
|---|---|---|---|
| MEVPRO-2 | Phase 3 randomized, double-blind, placebo-controlled study of PF 06821497 (Mevrometostat) with Enzalutamide in castration-resistant stage IV prostate cancer | Ver Estudio | Prostate cancer |
- Home
- Clinical Trials
- Press
- Contact
